Outcomes-Based Drug Pricing Still In Early Stages, HHS Forum Speakers Say
Executive Summary
Despite a few examples of outcomes-based pricing contracts in the US, comments at the HHS Pharmaceutical Forum suggest there are still significant obstacles preventing those types of contracts from being a near-term solution to high drug costs.